Cryoport, Inc. (CYRX) Q1 2026 Earnings Call Transcript
CryoPort, Inc. (CYRX) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.2. This compares to a loss of $0.22 per share a year ago.
Cryoport receives a buy rating with a $9.1 price target, implying 17% upside by FY 2026. CYRX demonstrated double-digit revenue growth in Q4 2025, led by Life Sciences Services, and improved gross margins to 47.8%. Management targets positive adjusted EBITDA in H2 2026, supported by cost reductions and a strengthened partnership with DHL.
| Air Freight & Logistics Industry | Industrials Sector | Jerrell W. Shelton CEO | XMUN Exchange | US2290503075 ISIN |
| US Country | 738 Employees | - Last Dividend | 5 Feb 2010 Last Split | 15 Mar 2005 IPO Date |
Cryoport, Inc. is a pivotal player in the temperature-controlled supply chain industry, specializing in solutions for various sectors including biopharma/pharma, animal health, and human reproductive medicine. The company's reach spans across the Americas, Europe, the Middle East, Africa, and the Asia Pacific, making it a global provider. Established in 1999 and headquartered in Brentwood, Tennessee, Cryoport has carved a niche in offering innovative and reliable logistics and storage solutions tailored for the management of temperature-sensitive biological materials.